Allergan, Inc. Sustainability Profile
Allergan, Inc., a prominent player in the global pharmaceutical industry, is headquartered in the United States. Founded in 1948, the company has established itself as a leader in medical aesthetics, eye care, and neuroscience, with significant operations across North America, Europe, and Asia. Allergan is renowned for its innovative products, including the iconic Botox, which revolutionised cosmetic treatments, and a diverse portfolio of therapeutic solutions. The company’s commitment to research and development has led to numerous breakthroughs, solidifying its market position as a trusted provider of advanced healthcare solutions. With a focus on enhancing patient outcomes, Allergan continues to achieve notable milestones, making it a key player in the ever-evolving pharmaceutical landscape.
DitchCarbon Score
How does Allergan, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Allergan, Inc.'s score of 65 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Allergan, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years, as indicated by the absence of emissions figures. The company is a current subsidiary of AbbVie Inc., which means that any climate commitments or emissions data may be inherited from its parent organisation. Allergan's climate initiatives are aligned with those of AbbVie Inc., which has set various reduction targets and participates in industry-standard climate initiatives. However, specific reduction targets or achievements for Allergan itself have not been disclosed. The company is involved in initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are managed at the parent level. As a subsidiary, Allergan's climate commitments and performance metrics are likely influenced by AbbVie Inc.'s overarching sustainability strategies. This includes a focus on reducing Scope 1, 2, and 3 emissions, although specific figures for Allergan are not provided. In summary, while Allergan, Inc. does not present its own emissions data or specific reduction targets, it is part of a corporate family that is actively engaged in climate commitments through AbbVie Inc.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 402,448,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | - |
How Carbon Intensive is Allergan, Inc.'s Industry?
How Carbon Intensive is Allergan, Inc.'s Location?
Allergan, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Allergan, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
